Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat

Journal of Clinical Investigation

Volumn 98, Issue 11, 1996, Pages 2440-2445

  Tseng, Chi Chuan ^a   Kieffer, Timothy J ^b   Jarboe, Linda A ^a   Usdin, Ted B ^c   Wolfe, M Michael ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

GIP receptor; glucagonlike peptide 1 (7 36) (GLP 1); incretin; insulin

Indexed keywords

CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENETIC TRANSFECTION; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INTRAPERITONEAL DRUG ADMINISTRATION; KILLER CELL; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT;

EID: 0029834106     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119060     Document Type: Article

References (33)

1. Creutzfeldt, W., and R. Ebert. 1985. New developments in the incretin concept today. Diabetologia. 28:565-573.
2. Unger, R.H., and A.M. Eisentraut. 1969. Entero-insular axis. Arch. Intern. Med. 123:261-266.
3. Ebert, R., and W. Creutzfeldt. 1987. Gastrointestinal peptides and insulin secretion. Diab. Metab. Rev. 3:1-16.
4. Dupré, J. 1991. The Endocrine Pancreas. Raven Press, New York. 253 pp.
5. Dupré, J., S.A. Ross, D. Watson, and J.C. Brown. 1973. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37:826-828.
6. Nauck, M., W. Schmidt, J. Ebert, J. Strietzel, P. Cantor, G. Hoffman, and W. Creutzfeldt. 1989. Insulinotropic properties of synthetic human gastric inhibitory peptide in man: interaction with glucose, phenylalanine, and cholecystokinin 8. J. Clin. Endocrinol. Metab. 69:654-662.
7. Kreymann, B., G. Williams., M.A. Ghatei, and S.R. Bloom. 1987. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. ii:1300-1304.
8. Mojsov, S., G.C. Weir, and J.F. Habener. 1987 Insulinotropin: glucagon-like peptide 1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79:616-619.
9. Schmid, R., V. Schusdziarra, R. Aulehner, N. Weigert, and M. Classen. 1990. Comparison of GLP-1 and GIP on release of somatostatin-like immunoreactivity and insulin from the isolated rat pancreas. Z. Gastroenterol. 28: 280-284.
10. Suzuki, S., K. Kawai, S. Ohashi, H. Mukai, Y. Murayana, and K. Yamashita. 1990. Reduced insulinotropic effects of glucagon-like peptide I-amide and GIP in isolated perfused diabetic rat pancreas. Diabetes. 39:1320-1325.
11. Siegel, E.G., A. Schulze, W.E. Schmidt, and W. Creutzfeldt. 1992. Comparison of the effect of GIP and GLP-1 on insulin release from rat pancreatic islets. Eur. J. Clin. Invest. 22:154-157.
12. Shima, K., M. Hirota, and C. Ohboshi. 1988. Effect of GLP-1 on insulin secretion. Regul. Pept. 22:245-252.
13. Wang, Z., R.M. Wang, A.A. Owji, D.M. Smith, M.A. Ghatei, and S.R. Bloom. 1995. Glucagon-like peptide-1 is a physiological incretin in rat. J. Clin. Invest. 95:417-421.
14. Wheeler, M.B., R.W. Gelling, C.H.S. McIntosh, J. Georgiou, J.C. Brown, and R.A. Pederson. 1995. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology. 136:4629-4639.
15. Gremlich, S., A. Porret, E.H. Hani, D. Cherif, N. Vionnet, P. Froguel, and B. Thorens. 1995. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes. 44:1202-1208.
16. Tseng, C.-C., L.A. Jarboe, S.B. Landau, E.K. Williams, and M.M. Wolfe. 1993. Glucose-dependent insulinotropic peptide: Structure of the precursor and tissue-specific expression in rat. Proc. Natl. Acad. Sci. USA. 90:1992-1996.
17. Usdin, T.B., E. Mezey, D.C. Button, M.J. Brownstein, and T.I. Bonner. 1993. GIP receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 133:2861-2870.
18. Hunter, M.W., and F.C. Greenwood. 1962. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature (Lond.). 194: 495-498.
19. Kieffer, T.J., B. Verchere, C.D. Fell, Z. Huang, J.C. Brown, and R.A. Pederson. 1993. Glucose-dependent insulinotropic polypeptide stimulated insulin release from as tumor-derived β-cell line. Can. J. Physiol. Pharmacol. 71: 917-922.
20. Efrat, S., S. Linde, H. Kofod, D. Spector, M. Delannoy, S. Grant, D. Hanahan, and S. Baekkeskov. 1988. β-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogen. Proc. Natl. Acad. Sci. USA. 85:9037-9041.
21. Xu, Z.-X., and S. Melethil. 1990. Simultaneous sampling of blood, bile, and urine in rats for pharmacokinetic studies. J. Pharmacol. Method. 24:203-208.
22. Winsett, O.E., C.M. Townsend, and J.C. Thompson 1985. Rapid and repeated blood sampling in the conscious laboratory rat: a new technique. Am. J. Physiol. 249:G145-146.
23. Cleator, I.G.M., and R.H. Gourlay. 1975. Release of immunoreactive gastric inhibitory polypeptide by oral ingestion of food substances. Am. J. Surg. 130:128-135.
24. Nauck, M.A., E. Hornberger, E.g., Siegel, R.C. Allen, R.P. Eaton, R. Ebert, and W. Creulzfeldt. 1986. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide response. J. Clin. Endocrinol. Metab. 63:492-498.
25. Nauck, M., F. Stockmann, R. Ebert, and W. Creutzfeldt. 1986. Reduced incretin effect in type 2 diabetes. Diabetologia. 29:46-52.
26. Salera, M., P. Giacomoni, L. Pironi, C. Ustra, M. Capelli, A. Georgi, M. Miglioli, and L. Barbara. 1983. Circadian rhythm of gastric inhibitory polypeptide in man. Metabolism. 32:21-24.
27. Kreymann, B., M.A. Ghatei, G. Williams, and S.R. Bloom. 1987. Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet. ii:1300-1304.
28. Ørskov, C., and J.J. Holst. 1987. Radioimmunoassays for glucagon-like peptides 1 and 2. Scand. J. Clin. Lab. Invest. 47:165-174.
29. Ørskov, C., J.U. Jeppesen, S. Madsbad, and J.J. Holst. 1991. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin. Invest. 87:415-423.
30. Shuster, L.T., V.L.W. Go, R.A. Rizza, P.C. O'Brien, and F.J. Service. 1988. Potential incretins. Mayo Clin. Proc. 63:794-800.
31. Nauck, M.A., E. Bartels, C. Ørskov, R. Ebert, and W. Creutzfeldt. 1993. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and GLP-1 (7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76:912-917.
32. Kolligs, F., H.C. Fehmann, R. Göke, and B. Göke. 1995. Reduction of the incretin effect in rats by the GLP-1 receptor antagonist exendin. Diabetes. 44:16-19.
33. 2 fragment with potent pancreatic amylase inhibitory activity. Regul. Pep. 39:9-17.